News

  • 27 October 2011

    Basilea completes BAL30072 antibiotic trial

    Basilea Pharmaceutical has completed a Phase I study to test the efficacy of its novel sulfactam antibiotic BAL30072 as a treatment of multi-drug resistant Gram-negative infections.

  • 26 October 2011

    Encap partners Lena to develop new drug delivery technology

    Encap Drug Delivery has collaborated with Lena Nanoceutics to develop Nano-Capsules, a new drug delivery technology that integrates Lena's proprietary nano-particle engineering technology with Encap's liquid-filled hard capsule technology.

  • 26 October 2011

    Lilly to withdraw sepsis drug Xigris

    Eli Lilly will withdraw its sepsis medication Xigris following results from a recent study that showed no benefit in taking the drug.

  • 26 October 2011

    Alemtuzumab found superior to standard MS treatment

    Sanofi and its subsidiary Genzyme have reported new results from the CARE-MS I trial, comparing the investigational drug Lemtrada (alemtuzumab) to Rebif (high-dose subcutaneous interferon beta-1a) in patients with relapsing-remitting...

  • 25 October 2011

    Teva and Dr Reddy’s pounce with Zyprexa generics

    Generic drug makers Teva Pharmaceutical Industries and Dr Reddy's Laboratories have announced the commercial launch of olanzapine tablets, a generic version of Eli Lilly antipsychotic Zyprexa.

Close
Close
Close

Go Top